2021, Número 1
<< Anterior Siguiente >>
Rev Hematol Mex 2021; 22 (1)
Biomarcadores clínicos y séricos de pronóstico en linfoma difuso de células B grandes
Aranda-Gutiérrez A, Hernández-Hernández JA, López-SánchezRC, Villela L
Idioma: Ingles.
Referencias bibliográficas: 58
Paginas: 30-43
Archivo PDF: 277.42 Kb.
RESUMEN
El linfoma difuso de células B grandes (LDCBG) es una neoplasia maligna agresiva con
tasas significativas de recaída a pesar del tratamiento de primera línea con regímenes
de quimioterapia basados en antraciclinas y rituximab. Hay varios índices disponibles
para estimar las tasas de supervivencia en pacientes con linfoma difuso de células B
grandes. Los que se usan más comúnmente son el Índice de pronóstico internacional
(IPI), el IPI revisado (R-IPI) y la Red nacional integral del cáncer-IPI (NCCN-IPI). Sin
embargo, estos índices no reconocen un subgrupo de pacientes con resultados muy
deficientes en la era del rituximab. Las tecnologías modernas han permitido la identificación
de factores de pronóstico molecular no contemplados en IPI, R-IPI o NCCN-IPI
que pueden identificar a pacientes con resultados desalentadores. Sin embargo, estas
tecnologías suelen ser caras, técnicamente desafiantes y requieren mayor validación
y estandarización. Por tanto, si bien los factores de pronóstico molecular se vuelven
más fácilmente disponibles, es importante considerar otras herramientas más simples
y económicas que puedan complementar los índices de pronóstico conocidos. Esta
revisión se centrará en los biomarcadores de laboratorio de pronóstico obtenidos en el
momento del diagnóstico en pacientes con linfoma difuso de células B grandes tratados
con regímenes que contienen rituximab.
REFERENCIAS (EN ESTE ARTÍCULO)
Tilly H, Gomes da Silva M, Vitolo U, Jack A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; Suppl 5: v116-25. doi. 10.1093/annonc/mdv304.
Jamil MO, Mehta A. Diffuse large B-cell lymphoma: Prognostic markers and their impact on therapy. Expert Rev Hematol 2016. doi. 10.1586/17474086.2016.1146584.
Shimono J, Takahashi S, Takemura R, Kakinoki Y. Useful prognostic tools based on complete blood cell counts in diffuse large B-cell lymphoma. Int J Lab Hematol 2019. doi. 10.1111/ijlh.13106.
Ruppert AS, Dixon JG, Salles G, Wall A, et al. International prognostic indices in diffuse large B-cell lymphoma: A comparison of IPI, R-IPI, and NCCN-IPI. Blood 2020; 135 (23): 2041-2048. doi. 10.1182/BLOOD.2019002729.
Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol 2019; 94 (5): 604-616. doi. 10.1002/ajh.25460.
Tisi MC, Bozzoli V, Giachelia M, Massini G, et al. Anemia in diffuse large B-cell non-Hodgkin lymphoma: The role of interleukin- 6, hepcidin and erythropoietin. Leuk Lymphoma 2014; 55. doi. 10.3109/10428194.2013.802314.
Clausen MR, Maurer MJ, Ulrichsen SP, Larsen TS, et al. Pretreatment hemoglobin adds prognostic information to the nccn-ipi in patients with diffuse large b-cell lymphoma treated with anthracycline-containing chemotherapy. Clin Epidemiol 2019; 11: 987-996. doi. 10.2147/CLEP.S219595.
Candelaria M, Reynoso-Noverón N, Ponce M, Castillo-Llanos R, et al. A prognostic score for survival in patients older than 65 years with diffuse large B-cell lymphoma. Rev Investig Clin 2018; 70 (1): 46-52. doi. 10.24875/ric.18002450.
Nakayama S, Matsuda M, Adachi T, Sueda S, et al. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era. Platelets 2019; 30. doi. 10.1080/09537104.2018.1499889.
Chen LP, Lin SJ, Yu MS. Prognostic value of platelet count in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 2012; 12 (1): 32-7. doi. 10.1016/j.clml.2011.09.215.
Ochi Y, Kazuma Y, Hiramoto N, Ono Y, et al. Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma. Ann Hematol 2017; 96: 1-8. doi. 10.1007/s00277-016-2819-3.
Zhao P, Zang L, Zhang X, Chen Y, et al. Novel prognostic scoring system for diffuse large B-cell lymphoma. Oncol Lett 2018; 5325-5332. doi. 10.3892/ol.2018.7966.
Wilcox RA, Ristow K, Habermann TM, Inwards DJ, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011; 25: 1502-1509. doi. 10.1038/leu.2011.112.
Markovic O, Popovic L, Marisavljevic D, Jovanovic D, et al. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. Eur J Intern Med 2014; 25 (3): 296-302. doi. 10.1016/j.ejim.2014.01.019.
Batty N, Ghonimi E, Feng L, Fayad L, et al. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-chop. Clin Lymphoma Myeloma Leuk 2013; 13: 15-18. doi. 10.1016/j. clml.2012.09.009.
Aoki K, Tabata S, Yonetani N, Matsushita A, et al. The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era. Acta Haematol 2013; 130 (4): 242-6. doi. 10.1159/000350484.
Koh YW, Park CS, Yoon DH, Suh C, et al. Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients? Eur J Haematol 2014; 93 (4): 340-8. doi. 10.1111/ejh.12354.
Ho CL, Lu CS, Chen JH, Chen YG, et al. Neutrophil/lymphocyte ratio, lymphocyte/monocyte ratio, and absolute lymphocyte count/absolute monocyte count prognostic score in diffuse large B-cell lymphoma: Useful prognostic tools in the rituximab era. Medicine (Baltimore) 2015. doi. 10.1097/MD.0000000000000993.
Lin B, Chen C, Qian Y, Feng J. Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: A meta-analysis. Leuk Lymphoma 2015; 56 (9): 2563-8. doi. 10.3109/10428194.2015.1014367.
Xia WK, Lin QF, Shen D, Liu ZL, et al. Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: A systematic review and meta-analysis. FEBS Open Bio 2016. doi. 10.1002/2211-5463.12066.
Sun HL, Pan YQ, He BS, Nie Z, et al. Prognostic performance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: An updated meta-analysis of eleven reports. Onco Targets Ther 2016; 9: 3017-3023. doi. 10.2147/OTT.S96910.
Cox MC, Nofroni I, La Verde G, Ferrari A, et al. Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 2008. doi. 10.1111/j.1365- 2141.2008.07028.x.
Cox MC, Nofroni I, Ruco L, Amodeo R, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuselarge- B-cell-lymphoma. Leuk Lymphoma 2008; 1745-1751. doi. 10.1080/10428190802226425.
Bari A, Marcheselli L, Sacchi S, Marcheselli R, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 2009; 21: 1486-1491. doi. 10.1093/annonc/mdp531.
Huang YC, Liu CY, Lu HJ, Liu HT, et al. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era. Ann Hematol 2013; 92 (11): 1513-20. doi. 10.1007/s00277-013-1807-0.
Maurer MJ, Jais JP, Ghesquières H, Witzig TE, et al. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol 2016; 91: 179-184. doi. 10.1002/ajh.24223.
Keane C, Tobin J, Talaulikar D, Green M, et al. A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival. Oncotarget 2018; 9: 23620-23627. doi. 10.18632/oncotarget.25306.
Chen Y, Neelapu S, Feng L, Bi W, et al. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol 2016; 175: 290-299. doi. 10.1111/bjh.14237.
Porrata LF, Ristow K, Habermann T, Inwards DJ, et al. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol 2010; 85: 896-899. doi. 10.1002/ajh.21849.
Troppan K, Deutsch A, Gerger A, Stojakovic T, et al. The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer 2014; 110: 369-374. doi. 10.1038/ bjc.2013.763.
Beltrán BE, Villela L, Torres MA, Otero V, et al. A multiinstitutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio in patients with diffuse large B-cell lymphoma: A study from the Latin American Group of Lymphoproliferative Disorders (GELL). Clin Lymphoma Myeloma Leuk 2020; 20: 637-646. doi. 10.1016/j. clml.2020.04.016.
Go SI, Park S, Kim JH, Kim HR, et al. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma. Tumori 2018; 104 (4): 292- 299. doi. 10.5301/tj.5000694.
Keam B, Ha H, Kim TM, Jeon YK, et al. Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 2015; 56 (7): 2032-8. doi. 10.3109/10428194.2014.982642.
Peyrade F, Jardin F, Thieblemont C, Thyss A, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Oncol 2011; 12 (5): 460-8. doi. 10.1016/S1470- 2045(11)70069-9.
Dalia S, Chavez J, Little B, Bello C, et al. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol 2014; 93: 1305-1312. doi. 10.1007/s00277-014-2031-2.
Gang AO, Pedersen M, d'Amore F, Pedersen LM, et al. A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: Population-based analysis from the Danish Lymphoma Registry. Leuk Lymphoma 2015; 2556-2562. doi. 10.3109/10428194.2015.1010078.
Melchardt T, Troppan K, Weiss L, Hufnagl C, et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2-microglobulin. Br J Haematol 2015. doi. 10.1111/bjh.13116.
Kobayashi T, Kuroda J, Yokota I, Tanba K, et al. The Kyoto prognostic index for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Cancer J 2016; 6 (1): e383. doi. 10.1038/bcj.2015.111.
Miura K, Konishi J, Miyake T, Makita M, et al. A host-dependent prognostic model for elderly patients with diffuse large b-cell lymphoma. Oncologist 2017; 22 (5): 554-560. doi. 10.1634/theoncologist.2016-0260.
Liu H, Zhang C, Feng R, Li J, et al. Validation and refinement of the age, comorbidities, and albumin index in elderly patients with diffuse large B-cell lymphoma: An effective tool for comprehensive geriatric assessment. Oncologist 2018; 23 (6): 722-729. doi. 10.1634/theoncologist.2017-0361.
Kim SH, Go S Il, Seo J, Hee KM, et al. Prognostic impact of pretreatment albumin to globulin ratio in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res 2018; 71: 100-105. doi. 10.1016/j.leukres.2018.07.014.
Yue W, Liu B, Gao L, He M, et al. The pretreatment albumin to globulin ratio as a significant predictor in patients with diffuse large B cell lymphoma. Clin Chim Acta 2018; 485: 316-322. doi. 10.1016/j.cca.2018.07.015.
Go S Il, Park S, Kang MH, Kim HG, et al. Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma. Ann Hematol 2019; 98 (2): 401-411. doi. 10.1007/ s00277-018-3540-1.
Nagata A, Kanemasa Y, Sasaki Y, Nakamura S, et al. Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B-cell lymphoma. Hematol Oncol 2020. doi. 10.1002/hon.2732.
Wight JC, Chong G, Grigg AP, Hawkes EA. Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. Blood Rev 2018; 5: 426-432. doi. 10.1016/j.blre.2018.03.005.
Montalbán C, Díaz-López A, Dlouhy I, Rovira J, et al. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol 2017; 176 (6): 918- 928. doi. 10.1111/bjh.14489.
Hong J, Kim SJ, Chang MH, Kim JA, et al. Improved prognostic stratification using NCCN- and GELTAMOinternational prognostic index in patients with diffuse large B-cell lymphoma. Oncotarget 2017; 2171-92182. doi. 10.18632/ oncotarget.20988.
Kang J, Yoon S, Suh C. Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Res 2017; 52 (4): 276-284. doi. 10.5045/br.2017.52.4.276.
Kanemasa Y, Shimoyama T, Sasaki Y, Tamura M, et al. Beta-2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B-cell lymphoma. Hematol Oncol 2016. doi. 10.1002/hon.2312.
Gao R, Liang JH, Wang L, Zhu HY, et al. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma. Int J Cancer 2018. doi. 10.1002/ijc.31590.
Lu TX, Wu S, Cai DY, Hong TT, et al. Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma. BMC Cancer 2019. doi. 10.1186/s12885-019-5758-2.
Drake MT, Maurer MJ, Link BK, Habermann TM, et al. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol 2010; 28. doi. 10.1200/JCO.2010.28.6674.
Bittenbring JT, Neumann F, Altmann B, Achenbach M, et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 2014. doi. 10.1200/ JCO.2013.53.4537.
Hohaus S, Tisi MC, Bellesi S, Maiolo E, et al. Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. Cancer Med 2018. doi. 10.1002/cam4.1166.
Troppan KT, Schlick K, Deutsch A, Melchardt T, et al. Creactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer 2014; 111: 55-60. doi. 10.1038/bjc.2014.277.
Sun F, Zhu J, Lu S, Zhen Z, et al. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era. BMC Cancer 2018. doi. 10.1186/s12885-017-3931-z.
Li X, Zhang Y, Zhao W, Liu Z, et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol 2015; 94: 57-63. doi. 10.1007/s00277-014-2167-0.
Hao X, Wei Y, Wei X, Zhou L, et al. Glasgow prognostic score is superior to other inflammation-based scores in predicting survival of diffuse large B-cell lymphoma. Oncotarget 2017; 8: 76740-76748. doi. 10.18632/oncotarget. 20832.
Texto completo
Cómo citar este artículo
Artículos similares